Acadian Asset Management
ADCT icon

Acadian Asset Management’s ADC Therapeutics ADCT Stock Holding History

Acadian Asset Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.68M Sell
449,122
-79,843
-15% -$315K ﹤0.01% 1009
2025
Q4 		$1.86M Buy
528,965
+301,465
+133% +$1.22M ﹤0.01% 938
2025
Q3 		$906K Buy
+227,500
New +$717K ﹤0.01% 1081
2024
Q3 		– Sell
-16,454
Closed -$51K – 2052
2024
Q2 		$51K Buy
+16,454
New +$65.4K ﹤0.01% 1603
2024
Q1 		– Sell
-144,858
Closed -$240K – 1546
2023
Q4 		$240K Sell
144,858
-11,190
-7% -$10.3K ﹤0.01% 1201
2023
Q3 		$138K Buy
156,048
+134,186
+614% +$178K ﹤0.01% 1256
2023
Q2 		$45K Buy
+21,862
New +$49.2K ﹤0.01% 1545
2023
Q1 		– Sell
-2,695
Closed -$10K – 1715
2022
Q4 		$10K Buy
+2,695
New +$10.8K ﹤0.01% 1736

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Acadian Asset Management's ADCT Position: Q1 2026 in Review

Acadian Asset Management reduced its ADC Therapeutics (ADCT) stake by 15% in Q1 2026, selling an estimated $315K and leaving 449,122 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #1009.

Acadian Asset Management first reported a position in ADCT in Q4 2022 and has held it in 8 quarters since. The position peaked at $1.86M in Q4 2025. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Acadian Asset Management held 449,122 shares of ADC Therapeutics worth $1.68M as of Q1 2026.
  • Acadian Asset Management sold 79,843 ADC Therapeutics shares in Q1 2026, an estimated $315K.
  • ADC Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1009 holding.
  • Acadian Asset Management first reported a position in ADC Therapeutics in Q4 2022 and has held it in 8 quarters since.
  • Acadian Asset Management's ADC Therapeutics position peaked at $1.86M in Q4 2025.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.